Photocure ASA

Earnings Release • Sep 23, 2014

Photocure: Expert consensus on the optimal use of Cysview® BLC published in Nature Reviews Urology

Photocure: Expert consensus on the optimal use of Cysview® BLC published in Nature Reviews Urology

Cysview® improves detection of Non-Muscle Invasive Bladder Cancer (NMIBC) beyond

that achieved with current standard of care

Oslo, Norway, 23 September 2014:  Photocure ASA (OSE: PHO), a specialty

pharmaceutical company focused on photodynamic technologies in dermatology and

cancer, is pleased to note that an expert consensus statement[1] on the optimal

use of Blue Light Cystoscopy with Cysview (HAL-BLC) in the United States has

been published in Nature Reviews Urology.

(http://www.nature.com/nrurol/journal/vaop/ncurrent/abs/nrurol.2014.245.html)

Blue Light Cystoscopy (BLC) with Cysview is an advancement in detection and

management of Non-Muscle Invasive Bladder Cancer (NMIBC) and is becoming

standard of care in many large institutions across the United States due to the

advantageous clinical benefit/risk ratio. Hexvix/Cysview has been used in

250 000 procedures to date, with consistent evidence that it improves detection

and management compared to White Light Cystoscopy (WLC) alone.

An expert panel of 16 American board certified Urologists and 1 European

Urologist reviewed existing published clinical evidence supporting the use of

Blue Light Cystoscopy with Cysview (HAL-BLC) for patients with NMIBC, including

European recommendations for its use and provided their own expert opinion on

which patients should receive HAL-BLC.

The panel proposed that the use of HAL-BLC in appropriate patient types will

result in better disease management, leading to potential reduced risk of

recurrence and prolonged time to recurrence. Improved detection and reduced risk

of recurrence is in turn associated with lower overall costs in managing bladder

cancer compared to WLC.

Dr. Sia Daneshmand, Director of Urologic Oncology and Associate Professor of

Urology at Institute of Urology, Norris Comprehensive Cancer Center at

University of Southern California and lead author, stated: "The consensus panel

recommendation outlines how urologists should incorporate HAL-BLC into their

clinical practice for the management of bladder cancer and the appropriate

patient types that would benefit from the technology. HAL-BLC results in a more

complete transurethral resection of bladder tumors (TURBT) and more accurate

staging, resulting in more appropriate management decisions.  The evidence shows

not only reduced risk of recurrence but also prolonged time to recurrence."

Kjetil Hestdal, President and CEO of Photocure, said: "Bladder cancer affects

550,000 people in the U.S., with 74,690 newly diagnosed patients every year.

Approximately 15,580 patients die from the disease each year due to of

recurrence of the cancer.  The consensus statement clearly outlines the benefits

of Blue Light Cystoscopy with Cysview and its positive impact on the diagnosis

and management of bladder cancer in multiple patient types. We believe the

adoption of HAL-BLC will bring significant benefit to urologists, patients and

payers fighting the disease."

The panel members also discussed key factors that must be considered for

incorporation of HAL-BLC into routine clinical practice in the United States,

including economic considerations and identification of stakeholders.

The consensus panel recommended that HAL-BLC should be considered

* For initial diagnosis of NMIBC

* For detection of recurrent tumors

* In patients with positive urine cytology but negative white light cystoscopy

(WLC) findings

* For optimal tumor staging

The panel concluded that extensive evidence and clinical experience show that

HAL-BLC can improve the detection of NMIBC beyond that achieved with the current

standard of care, WLC.

The consensus opinion of the US expert panel is in line with the opinions of

European colleagues, namely that HAL-BLC has a role in the initial diagnosis of

patients suspected to have NMIBC, as well as for management of recurrent bladder

cancer. The European Consensus publication "Witjes JA, et al. Clinical and Cost

Effectiveness of Hexaminolevulinate-guided Blue-light Cystoscopy: Evidence

Review and Updated Expert Recommendations. Eur Urol (2014)" can be viewed here.

For further information, please contact:

Photocure

President & CEO Kjetil Hestdal

Tel: + 47 913 19 535, Email: kh@photocure.no

CFO Erik Dahl

Tel: +47 50 55 000, Email: ed@photocure.no

Hume Brophy

Mary Clark, Hollie Vile, Supriya Mathur

Tel: +44 20 3440 5653, Email: photocure@humebrophy.com

Notes to editors

About Photocure ASA

Photocure ASA, headquartered in Oslo Norway, is a specialty pharmaceutical

company and world leader in photodynamic technology. Based on our unique

proprietary Photocure Technology(TM) platform, Photocure develops and

commercializes highly selective and effective solutions within disease areas

with high unmet medical need, such as bladder cancer, HPV and precancerous

cervical lesions, colorectal cancer and skin conditions. Our aim is to provide

solutions which can improve health outcomes for patients worldwide. Photocure is

listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is

available at www.photocure.com.

--------------------------------------------------------------------------------

[1] Consensus Conference on Blue Light Cystoscopy with Cysview sponsored by

Photocure and KARL STORZ Endoscopy-America.

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#1857712]